Lung Cancer

Lung Cancer

FDA Grants Accelerated Approval to Neladalkib for ALK-Positive NSCLC

November 17 2 min read
Today, neladalkib (Nelkarmi), a kinase inhibitor, was granted accelerated approval for adults with previously treated, locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC).

Latest in Lung Cancer